It is an exciting time for cell, gene and regenerative therapies in Japan, helped by a much improved and highly supportive regulatory environment. But continuing discussions with regulators are essential if industry concerns, particularly in the pricing area, are to be reflected in policy, stresses the CEO of Athersys Inc.
Dr Gil Van Bokkelen, chairman and CEO of the US stem cell venture, is generally optimistic on the present environment...







